Last reviewed · How we verify
Systemic oncological treatment
At a glance
| Generic name | Systemic oncological treatment |
|---|---|
| Also known as | chemotherapy, radiotherapy |
| Sponsor | Fundación GECP |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
- Step Count and Treatment Response in Neoadjuvant Breast Cancer
- Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy (PHASE3)
- Characteristics of Sexual Dysfunction in Patients With Lung Cancer
- Preoperative Radiation Therapy and Immediate Breast Reconstruction (NA)
- A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients (NA)
- PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Systemic oncological treatment CI brief — competitive landscape report
- Systemic oncological treatment updates RSS · CI watch RSS
- Fundación GECP portfolio CI